APG-2305
APG-2305 is a selective IL-23 receptor inhibitor. APG-2305 inhibits IL-23-induced STAT3 phosphorylation, reduces the expression of pro-inflammatory cytokines (IL-1, IL-6, IL-22) without altering IL-17 levels, and alleviates inflammation in multiple in vivo models. APG-2305 is used for research on inflammatory autoimmune diseases.
For research use only. We do not sell to patients.
- Formula: C44H66N10O19
- Molecular Weight:1039.05
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[2]|
STAT3 |
IL-1 |
IL-6 |
IL-22 |
IL-23 |
In Vitro
APG-2305 (30 min) potently inhibits IL-23-induced STAT3 phosphorylation in primary mouse spleen cells with an IC50 of 1.5 nM[2].
APG-2305 (1 μM; 30 min) exhibits functional selectivity in IL-23R/IL-12Rβ1-expressing HEK-293 cells, inhibiting IL-23-induced expression of IL-1β, IL-6, and IL-22 but not IL-17A, p35, or p40[2].
APG-2305 selectively inhibits IL-23-induced IL-6 and IL-22 production but not IL-17 production in primary mouse spleen cells[2].
APG-2305 (1 μM; 30 min) inhibits IL-23-induced IL-1β and IL-6 gene expression but not IL-17 expression in Jurkat T-lymphocyte cells[2].
APG-2305 (1 μM; 30 min) does not modulate IL-12-induced cytokine gene expression in IL-12Rβ1/IL-12Rβ2-expressing HEK-293 cells[2].
APG-2305 (1 μM; 30 min) exerts a minimal effect on IL-23-induced cytokine expression in Raw Blue mouse macrophage cells[2].
APG-2305 (1 μM; 30 min) selectively inhibits IL-23-induced IL-1β and IL-6 gene expression but not IL-17 expression in human rheumatoid arthritis synoviocytes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:IL-23R/IL-12Rβ1-expressing HEK-293 cells
-
Concentration:1 μM (preincubation)
-
Incubation Time:30 min (preincubation); 4 h (IL-23 incubation)
-
Result:Effectively reduced IL-1β, IL-6, and IL-22 gene expression in IL-23-stimulated HEK-293 cells expressing the IL-23 receptor.
Did not significantly reduce IL-23-induced IL-17A, p35, and p40 mRNA levels.
-
Cell Line:Jurkat T-lymphocyte cells
-
Concentration:1 μM (preincubation)
-
Incubation Time:30 min (preincubation); 4 h (IL-23 incubation)
-
Result:Significantly reduced IL-23-induced gene expression of IL-1β and IL-6 in Jurkat cells.
Did not reduce IL-17 gene expression.
-
Cell Line:IL-12Rβ1/IL-12Rβ2-expressing HEK-293 cells
-
Concentration:1 μM (preincubation)
-
Incubation Time:30 min (preincubation); 4 h (IL-12 incubation)
-
Result:Did not interfere with IL-12-induced expression of IL-22, p35, and p40 genes in IL-12R-expressing HEK-293 cells.
-
Cell Line:Raw Blue mouse macrophage cells
-
Concentration:1 μM (preincubation); 100 ng/mL (ionomycin, pretreatment); 20 ng/mL (phorbol 12-myristate 13-acetate, pretreatment)
-
Incubation Time:30 min (preincubation); 24 h (ionomycin/phorbol 12-myristate 13-acetate pretreatment); 4 h (IL-23 incubation)
-
Result:Had only a minor effect on IL-23-induced IL-1β and IL-6 gene expression in Raw Blue mouse macrophages.
In Vivo
APG-2305 (10 mg/kg; i.p.) selectively attenuates a subset of serum inflammatory cytokines in anti-CD40-induced systemic inflammation, with no effect on liver inflammation[2].
APG-2305 (5 mg/kg; i.p.; twice daily; 21 days) inhibits 80% of clinical arthritis signs and reduces joint damage in the Collagen-induced arthritis mouse model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD-1 mice (male, 5 weeks old, ear inflammation induced by daily intradermal injection of mIL-23 into the external earlobe for 5 days)[2]
-
Dosage:5 mg/kg (total 10 mg·kg-1·day-1)
-
Administration:i.p.; twice daily; 5 days
-
Result:Inhibited ~50% of IL-23-induced ear edema.
Inhibited 50-75% of IL-1β, IL-6, and IL-22 mRNA expression induced by IL-23 in ear tissue.
Did not decrease IL-17 mRNA levels significantly.
-
Animal Model:C57BL/6 mice (male, 8-12 weeks old, systemic inflammation induced by a single intraperitoneal injection of anti-CD40 antibody)[2]
-
Dosage:10 mg/kg
-
Administration:i.p.; once daily
-
Result:Significantly attenuated serum levels of IL-2, IL-6, IL-12p70, IFN-γ, and CXCL1 induced by anti-CD40.
Decreased serum levels of IL-12p40, TNF-α, and CCL2 only marginally.
Did not reduce the severity of liver inflammation induced by anti-CD40.
-
Animal Model:DBA/1J mice (male, 8 weeks old, rheumatoid arthritis induced by intradermal immunization with bovine type II collagen emulsified in complete Freund's adjuvant at the base of the tail, followed by a boost with collagen in incomplete Freund's adjuvant on day 21)[2]
-
Dosage:5 mg/kg
-
Administration:i.p.; twice daily; 21 days
-
Result:Inhibited 80% of the clinical signs of collagen-induced arthritis, as measured by daily clinical scores and area under the clinical score curve.
Showed diminished joint damage in treated animals via radiological examination.
Revealed markedly reduced inflammatory signs in arthritic paws via histologic evaluation.
Chemical Information
-
Molecular Weight 1039.05
-
Formula C44H66N10O19
-
SMILES
O=C(N[C@H](CCC(O)=O)C(N[C@H](CCC(O)=O)C(N[C@H](CCC(O)=O)C(N[C@H](CCC(N)=O)C(N[C@H](CCC(N)=O)C(N[C@H](CC(C)C)C(N[C@H](CC1=CC=C(C=C1)O)C(O)=O)=O)=O)=O)=O)=O)=O)[C@@H]([C@@H](O)C)N
-
Sequence
D{Thr-Glu-Glu-Glu-Gln-Gln-Leu-Tyr}
-
Sequence Shortening
D{TEEEQQLY}
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)